RAPS.org needs your explicit consent to store browser cookies. If you don't allow cookies, you may not be able to use certain features of the web site such as personalized content. Please see our Privacy Policy for more information.

RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus Articles RSS Feed 2.0
24 November 2020
Health care workers would be among the first to receive vaccines against COVID-19 in a timeline presented to the Centers for Disease Control and Prevention’s (CDC’s) vaccines advisory committee. The proposed scheme would have essential workers nex...
Sponsored Content Sponsored Content
20 September 2020
Is your clinical trial data “submission-ready”?  Make the right decisions for your data to prevent delays.
Sponsored Content Sponsored Content
01 September 2020
Submitting your NDA on time is critical. Learn how to overcome timeline challenges with this success story.

Latest News

ALL
Following an announcement by outgoing President Donald Trump on Friday, the Department of Health and Human Services (HHS) is moving to end the Food and Drug Administration’s (FDA) unapproved drugs initiative, which the agency claims has led to inc...
Guidance from the Indian Department of Pharmaceuticals clarifies how companies can take advantage of an order intended to encourage the use of local suppliers of medical devices.
The World Health Organization is revising its guidance to industry on good manufacturing practices for investigational drug products, including new recommendations for quality risk management
24 November 2020
The US Food and Drug Administration (FDA) on Monday launched a new cloud-based submission portal for orphan drug designation requests, shifting away from the current paper and CD-based submission process.
Updated 23 November to include the US FDA emergency use authorization of casirivimab and imdevimab (REGN-COV2).
COVID-19 vaccine tracker 23 November 2020
Updated 23 November  with new information on the vaccine candidate from AstraZeneca/University of Oxford.